-
公开(公告)号：AU2007311689B2
公开(公告)日：2013-05-16
申请号：AU2007311689
申请日：2007-10-18
Applicant: UCB PHARMA SA
Inventor： POPPLEWELL ANDREW GEORGE , ADAMS RALPH , RAPECKI STEPHEN EDWARD
IPC: C07K16/24 , A61K39/395 , A61P35/00 , A61P37/06 , C12N15/13
Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
-
22.发明专利
公开(公告)号：DK2230308T3
公开(公告)日：2013-05-06
申请号：DK09176251
申请日：2001-06-05
Applicant: UCB PHARMA SA
-
23.发明专利
公开(公告)号：PT2230308E
公开(公告)日：2013-05-03
申请号：PT09176251
申请日：2001-06-05
Applicant: UCB PHARMA SA
-
公开(公告)号：AU2013203712A1
公开(公告)日：2013-05-02
申请号：AU2013203712
申请日：2013-04-11
Applicant: BIOGEN MA INC , UCB PHARMA SA
Inventor： BURKLY LINDA , FERRANT-ORGETTAS JANINE L , GARBER ELLEN A , ADAMS RALPH , BROWN DEREK THOMAS , POPPLEWELL ANDREW GEORGE , ROBINSON MARTYN KIM , SHOCK ANTHONY , TYSON KERRY LOUISE , TAYLOR FREDERICK R , HSU YEN-MING , SU LIHE
IPC: C07K16/28 , A61K39/395 , C12N15/13 , C12N15/63
Abstract: Abstract This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD 154-CD40 interactions. FIGURE 19: inhibition of IgG Immune Response to Tetanus Toxoid in Cynomolgus Monkeys Primary Immune Response to TT -
-
25.发明专利
公开(公告)号：IS2808B
公开(公告)日：2012-09-15
申请号：IS6217
申请日：2002-01-03
Applicant: UCB PHARMA SA
-
Patent Agency Ranking
公开(公告)号：AU2005305677B2
公开(公告)日：2012-02-02
申请号：AU2005305677
申请日：2005-11-16
Applicant: UCB PHARMA SA
Inventor： ADAMS RALPH , RAPECKI STEPHEN EDWARD , TICKLE SIMON PETER , POPPLEWELL ANDREW GEORGE
Abstract: The invention relates to an antibody molecule having specificity for antigenic determinants of IL- 17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.
-
27.发明专利
公开(公告)号：HK1148776A1
公开(公告)日：2011-09-16
申请号：HK11102887
申请日：2011-03-22
Applicant: UCB PHARMA SA
Inventor： ATHWAL DILJEET SINGH , BROWN DEREK THOMAS , WEIR ANDREW NEIL CHARLES , POPPLEWELL ANDREW GEORGE , CHAPMAN ANDREW PAUL , KING DAVID JOHN
IPC: C12N20060101 , A61K39/395 , C12N15/09 , A61K47/48 , A61P20060101 , A61P19/02 , A61P29/00 , A61P37/06 , C07K20060101 , C07K16/24 , C07K16/46 , C12N1/21 , C12N15/13 , C12P21/02 , C12P21/08
Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNF± There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNF±
-
公开(公告)号：PL208848B1
公开(公告)日：2011-06-30
申请号：PL37034402
申请日：2002-10-10
Applicant: UCB PHARMA SA
-
公开(公告)号：DE60237778D1
公开(公告)日：2010-11-04
申请号：DE60237778
申请日：2002-10-10
Applicant: UCB PHARMA SA
-
公开(公告)号：AT482234T
公开(公告)日：2010-10-15
申请号：AT02800666
申请日：2002-10-10
Applicant: UCB PHARMA SA
Inventor： POPPLEWELL ANDREW GEORGE , TICKLE SIMON PETER , ZINKEWICH-PEOTTI KAREN , MORRISON ROBERT KENDALL
IPC: C07K16/28 , C12N15/09 , A61K39/395 , A61K47/48 , A61P17/00 , A61P17/06 , A61P19/02 , A61P29/00 , A61P35/00 , A61P35/04 , A61P37/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/13 , C12P21/02 , C12P21/08
Abstract: There are disclosed antibody molecules containing at least on CDR derived from a mouse monoclonal antibody having specificity for human KDR. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases in which VEGF and/or KDR are implicated.
-
-
-
-
-
-
-
-
-
Search Results
161
records
(took 0.024 seconds)
